Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05245292 · ClinicalTrials.gov registry record · Phase 1
3BNC117-LS and 10-1074-LS Plus N-803 (bNAb+N-803)
A Phase 1 study of Human Immunodeficiency Virus, sponsored by Rockefeller University.
- Active
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
- 3
- Study locations
NCT05245292 is a Phase 1 study of Human Immunodeficiency Virus that is active but no longer recruiting, run by Rockefeller University. The registered enrollment target is 28 participants, below the 183-participant average among 39 other Human Immunodeficiency Virus trials with a reported enrollment target (85% lower). The trial reports 3 study locations across 2 states.
The verdict
NCT05245292, a Phase 1 study of Human Immunodeficiency Virus, is active but no longer recruiting, sponsored by Rockefeller University.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
- 3
- Study locations
Study Summary
The proposed study is a phase 1, open label, single arm study to evaluate the safety and antiretroviral activity of the combination of two long-acting broadly neutralizing antibodies, 3BNC117-LS dosed once at 30 mg/kg and 10-1074-LS dosed once at 10 mg/kg, both intravenously (IV) at week 0, plus an IL-15 superagonist complex, N-803, dosed at 6 mcg/kg, subcutaneously (SC) at week 1 and then every 3 weeks for a total of 8 doses, in ART-treated adults living with HIV during analytical treatment interruption.
Conditions Studied
Interventions
- DRUG N803
- DRUG 3BNC117-LS
- DRUG 10-1074-LS
Study Locations (3)
New York
- Weill Cornell Medicine, Cornell Clinical Trials Unit - New York
- The Rockefeller University - New York
Pennsylvania
- Perelman School of Medicine University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2022-12-07 |
| Est. Completion | 2026-03-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05245292
The ClinicalTrials.gov registry entry for NCT05245292 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 183-participant average among 39 other Human Immunodeficiency Virus trials with a reported enrollment target (85% lower). The listed sponsor is Rockefeller University, which has 117 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Human Immunodeficiency Virus appearing as the primary indexed condition, and to 3 interventions - of which N803 is the first listed.
NCT05245292 reports 3 study locations spanning 2 distinct geographic areas - top geographies include New York, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05245292 about?
NCT05245292 is a clinical study titled "3BNC117-LS and 10-1074-LS Plus N-803 (bNAb+N-803)". The proposed study is a phase 1, open label, single arm study to evaluate the safety and antiretroviral activity of the combination of two long-acting broadly neutralizing antibodies, 3BNC117-LS dosed once at 30 mg/kg and 10-1074-LS dosed once at 10 mg/kg, both intravenously (IV) at week 0, plus an ...
What is the current status of trial NCT05245292?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2022-12-07. Estimated completion is 2026-03-31.
What conditions does trial NCT05245292 study?
This clinical trial studies the following conditions: Human Immunodeficiency Virus.
What interventions are being tested in trial NCT05245292?
The interventions under investigation include: N803 (DRUG), 3BNC117-LS (DRUG), 10-1074-LS (DRUG).
Who is sponsoring clinical trial NCT05245292?
This trial is sponsored by Rockefeller University, which has 117 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05245292 being conducted?
This trial has 3 study locations across New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Human Immunodeficiency Virus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Lenacapavir Intensification to Disrupt HIV Reservoirs in Virologically Suppressed People With HIV Receiving Antiretroviral Therapy
RECRUITING · Phase 1
-
First-in-human Study of 10-1074-LS Alone and in Combination With 3BNC117-LS
COMPLETED · Phase 1
-
Pharmacokinetic Interactions Between an Herbal Medicine (African Potato) and Antiretroviral Agents (Lopinavir/Ritonavir)
COMPLETED · Phase 1
-
Evaluation of the Safety of a Polyvalent Virus in Healthy Adults
COMPLETED · Phase 1
-
Evaluating Drug Interactions Between Doravirine With Estradiol and Spironolactone in Healthy Transgender Women
COMPLETED · Phase 1
-
First in Human Study of TLC-ART 101 (ACTU 2001)
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.